These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10700895)

  • 21. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
    Hayes DF; Van Zyl JA; Hacking A; Goedhals L; Bezwoda WR; Mailliard JA; Jones SE; Vogel CL; Berris RF; Shemano I
    J Clin Oncol; 1995 Oct; 13(10):2556-66. PubMed ID: 7595707
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A case of breast cancer with multiple bone metastases demonstrating complete remission with high-dose toremifene therapy].
    Saito Y; Amano S; Kashio M; Abe H; Kuboi Y; Sakurai K; Aoki N; Hata S; Negishi N
    Gan To Kagaku Ryoho; 2004 Jun; 31(6):911-4. PubMed ID: 15222111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.
    Braybrooke JP; Vallis KA; Houlbrook S; Rockett H; Ellmén J; Anttila M; Ganesan TS; Harris AL; Talbot DC
    Cancer Chemother Pharmacol; 2000; 46(1):27-34. PubMed ID: 10912574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combined effects of toremifene and paclitaxel on human breast cancer cell lines].
    Maruyama S; Kuroiwa S; Saimoto A; Nishikawa K
    Gan To Kagaku Ryoho; 2003 May; 30(5):669-75. PubMed ID: 12795099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
    Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Combined chemoendocrine therapy using adriamycin, cyclophosphamide and high dose toremifene in patients with recurrent breast cancer].
    Wada N; Kobayashi H; Oka S; Ando J; Tamura H
    Gan To Kagaku Ryoho; 2002 Nov; 29(11):1935-42. PubMed ID: 12465393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
    Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
    Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.
    Ellmén J; Werner D; Hakulinen P; Keiling R; Fargeot P; Falkson G; Bezwoda WR
    Cancer Chemother Pharmacol; 2000; 45(5):402-8. PubMed ID: 10803924
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Toremifene citrate (Fareston).
    Gerken P
    Clin J Oncol Nurs; 2004 Oct; 8(5):529-30. PubMed ID: 15565747
    [No Abstract]   [Full Text] [Related]  

  • 31. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of toremifene and its metabolites in patients with advanced breast cancer.
    Wiebe VJ; Benz CC; Shemano I; Cadman TB; DeGregorio MW
    Cancer Chemother Pharmacol; 1990; 25(4):247-51. PubMed ID: 2136809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic analysis of a combined chemoendocrine treatment with paclitaxel and toremifene for metastatic breast cancer.
    Saeki T; Okita A; Aogi K; Kakishita T; Okita R; Taira N; Ohama Y; Takashima S; Nishikawa K
    Breast Cancer; 2009; 16(2):113-20. PubMed ID: 18936884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of breast cancer with multiple bone metastases improved by high-dose toremifene].
    Doi T; Nishiyama K; Wakasugi J; Ootaki S; Kikuchi M; Kubota K; Yamamoto H
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):839-43. PubMed ID: 11432355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis.
    Hong J; Huang J; Shen L; Zhu S; Gao W; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
    BMC Cancer; 2020 Jul; 20(1):663. PubMed ID: 32677982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women.
    Gardner M; Taylor A; Wei G; Calcagni A; Duncan B; Milton A
    J Clin Pharmacol; 2006 Jan; 46(1):52-8. PubMed ID: 16397284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toremifene: an evaluation of its safety profile.
    Harvey HA; Kimura M; Hajba A
    Breast; 2006 Apr; 15(2):142-57. PubMed ID: 16289904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical benefit of high-dose toremifene for metastatic breast cancer.
    Koike K; Edo M; Higaki M; Kitahara K; Satou S; Noshiro H
    Gan To Kagaku Ryoho; 2013 Jul; 40(7):877-80. PubMed ID: 23863727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
    Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
    Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer.
    Torrisi R; Baglietto L; Johansson H; Veronesi G; Bonanni B; Guerrieri-Gonzaga A; Ballardini B; Decensi A
    Br J Cancer; 2001 Dec; 85(12):1838-41. PubMed ID: 11747323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.